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(57) ABSTRACT 
A method of synthesizing a compound having the formula 
via a cascade radical 4+1 annulation includes the step 
Wherein the precursor 
or the precursor 
is reacted With an arylisonitrile having the formula 
R1 
R3 NC 
Wherein X is a radical precursor such as Cl, Br or I. R6 is 
preferably —Si(R8R9R1O) or —(R7)Si(R8R9R1O), Wherein 
R7 is an alkylene group, an alkenylene group, or an alky 
nylene group; and R8, R9 and R10 are independently a CMO 
alkyl group, a C2_1O alkenyl group, a C2_1O alkynyl group, an 
aryl group or a —(CH2)NR11 group, Wherein N is an integer 
Within the range of 1 through 10 and R11 is a hydroxy group, 
alkoxy group, an amino group, an alkylamino group, a 
dialkylamino group, a halogen atom, a cyano group, —SRC 
or a nitro group. R1—R4 can be broadly substituted. R5 is 
preferably a CMO alkyl group, an alkenyl group, an alkynyl 
group, or a benZyl group. R13 is preferably H, F or —CH3. 
R16 is R16 is —C(O)Rf or H. The E-ring (the lactone ring) 
may be opened. 
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Synthesis of New AB-Ring Modi?ed Homosilatecan Derivitives 
NaH. LiBr 
DMFIDME 
10a, R6; SiMe3, 63% 
b, R6 = SiMeZtBu, 58% 
R6 R2 Yield 
0a SiMeZtBu NHBoc 15% 
11b SiMeZ'BU NH2 89%3 
1|c SiMe3 NHBoc 53% 3 
11a SiMe3 NH; 45% 
0e SiMeZ'Bu OAc 20% 3 
0f silvlez‘su OH 79% 
1g SiMeztBu H 27% 
11h SiMe3 H 37% 
FIG. 2A 
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General Route to A-, B-, and A/B Substituted Homocamptothecins 
I 
' I )l I N\ (K N O\ 
substituted _______,__ oxidative 
allyl alcohol / -——~ I *' MC(R“’)(R‘“)CO2R‘5 
o cleavage 
R5 R5 OC(O)H 
R“ N o\ 1)halogenative~ O s - 
1) Refo'matsky I / desilylation 1) R ‘2 
—.---.--~ - HN __ 
33mm‘! Rs 2) demethylation \ o 2) cascade radical reaction 
Y \ R1: 
Ho R5 R13 R‘[ 
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Fuorescence Emission Spectra of 1 pM DB-38 
lipid concentration 5 mM, xex = 410 nm, EX resolution 4nm, EM resolution 4nm, 
without lEM polarizer, HV=82D V 
in 538 C Kmax = 531 nm 
- _ - in P Xmax= 515 nm 
8 in Ethanol kex - 421 nm _ - in DMPG Kmax: 517 nm 
“ \ ‘ ‘_ in Ethanol kmax= 510 nm 
S - - in Ethanol 
5P, — in PBS 
>- 6 ~ -- in DMPC 
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Equilibrium binding of DB-38, [DB-81, DB-91, 
CPT and TPT to DMPC at 37°C 
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pH Dependence of the Stability of the B-OH Lactone Moiety 
of DB-91 
0.0 
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Comparison of the Stabilities of ci-Lactone Silateoans 
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Comparison of the Stabilities of ot-Lactone Silatecans 
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Stability of Homosilatecans in Red Blood Cells 
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Comparison of the Stabilities of or-Laotone Silatecans 
with their corresponding Homosilatecans in Whole Blood at 37°C 
1 o A 1.0 . 
O CHJ792 
o DB-38 
0.8 0 Q8 _ 
I DB-202 
o DB-81 
‘)5 - 0.6 . 
0.4 - _ 
LLI 
% 0.2 _ 0.2 _ |_ 
O 
< 
..J 0.0 . . , 0,0 I I I 
LI- 0 60 120 100 0 so 120 100 
O 
z 1.0 C Q R 
.- \Q\€ 
% 0.8 _ 
Ll. 
0.6 - 
0.4 _. \\ 
0 DB-67 0 05-204 
0.2 - O DB-91 0.2 < 0 [38-90 
I a I I r l 
0 60 120 180 0 60 120 180 
TIME (Min) 
FIG. 16 
U.S. Patent Jun. 25,2002 Sheet 18 0f 18 US 6,410,731 B2 
Comparison of the Stability of Homosilatecans with 
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